Latest News and Press Releases

-- Article outlines advantages and provides further data to support the use of COLVERA for assessing response to treatment and risk of disease progression – -- Study finds that a COLVERA positive...

BRIDGEWATER, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Clinical Genomics, a provider of cancer diagnostic solutions, including liquid biopsy tests for molecular residual disease (“MRD”) and recurrence...

BRIDGEWATER, N.J., June 14, 2021 (GLOBE NEWSWIRE) -- Clinical Genomics, a provider of cancer diagnostic solutions, including liquid biopsy tests for minimal residual disease (“MRD”) and recurrence...

-- New York State grants permit for CLIA laboratory, expanding access to COLVERA test to patients in all 50 states -- BRIDGEWATER, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Clinical Genomics (“CG”...

BRIDGEWATER, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Clinical Genomics (“CG” or the “Company”), a provider of cancer diagnostic solutions, including liquid biopsy tests, today announced that Novitas...

BRIDGEWATER, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Clinical Genomics (“CG” or the “Company”), a provider of colorectal cancer diagnostic solutions, including liquid biopsy tests, today announced...

BRIDGEWATER, N.J., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Clinical Genomics (“CG” or the “Company”), a provider of cancer diagnostic solutions, including liquid biopsy tests for recurrence monitoring of...

-- Building management team to support development and commercialization of innovative liquid biopsy tests, COLVERA®, for colorectal recurrence monitoring, and TRIDENT, for colorectal screening -- ...

BRIDGEWATER, N.J., May 27, 2020 (GLOBE NEWSWIRE) -- Clinical Genomics (“CG” or the “Company”), a provider of cancer diagnostic solutions, including liquid biopsy tests, today announced that the...

-- Advances key development milestones for the Trident Program -- -- Further strengthens strategic alliance with Quest Diagnostics focused on the Trident Program for CRC screening -- BRIDGEWATER,...